Introducing ADT-007: A Novel PAN-RAS Inhibitor with a Unique Mechanism of Action to Treat Pancreatic Cancer

Time: 2:00 pm
day: Day One Track A PM


  • Utilizing ultra-high potency and selectivity for killing cancer cells with activated RAS that acts independent of the mutation or isozyme
  • Achieving low potential for intrinsic or acquired resistance and off-target effects to effect a robust response
  • Showcasing antitumor activity in mouse tumor models with target engagement at well tolerated dosages
  • Developing an orally bioavailable prodrug to treat pancreatic cancer